Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with Total Therapy 3.
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.
Blood. 2013 Jan 10. [Epub ahead of print]
PMID: 23305732
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Venkateshaiah SU, Khan S, Ling W, Bam R, Li X, van Rhee F, Usmani S, Barlogie B, Epstein J, Yaccoby S.
Exp Hematol. 2013 Feb 19. doi:pii: S0301-472X(13)00056-8. 10.1016/j.exphem.2013.02.008. [Epub ahead of print]
PMID: 23435312
http://www.ncbi.nlm.nih.gov/pubmed/23435312
Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor Levels.
Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F.
PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23.
PMID: 23372742
http://www.ncbi.nlm.nih.gov/pubmed/23372742
Role of Bruton's tyrosine kinase (BTK) in myeloma cell migration and induction of bone disease.
Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah SU, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S.
Am J Hematol. 2013 Mar 2. doi: 10.1002/ajh.23433. [Epub ahead of print]
PMID: 23456977